Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial

Gynecologic Oncology

Volumn 132, Issue 1, 2014, Pages 176-180

  Monk, Bradley J ^a   Kaye, Stanley B ^b   Poveda, Andrés ^c   Herzog, Thomas J ^d   Aracil, Miguel ^e   Nieto, Antonio ^e   Badri, Nadia ^e   Parekh, Trilok V ^f   Tanović, Adnan ^e   Galmarini, Carlos M ^e  

^a CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c Valencian Institute of Oncology   (Spain)

^d College of Physicians and Surgeons ^*  (United States)

^e PharmaMar ^*  (Spain)

^f JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Molecular marker; Nibrin; Ovarian cancer; Trabectedin

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA DEPENDENT PROTEIN KINASE; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FANCONI ANEMIA GROUP D2 PROTEIN; KI 67 ANTIGEN; NIBRIN; PROTEIN P53; RAD50 PROTEIN; TRABECTEDIN; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ADULT; ARTICLE; CANCER PROGNOSIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MIDDLE AGED; OVARY CANCER; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RECURRENT OVARIAN CANCER; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME;

MOLECULAR MARKER; NIBRIN; OVARIAN CANCER; TRABECTEDIN;

BIOLOGICAL MARKERS; CELL CYCLE PROTEINS; CYSTADENOCARCINOMA, SEROUS; DIOXOLES; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TETRAHYDROISOQUINOLINES; TREATMENT OUTCOME;

EID: 84892784737     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.10.032     Document Type: Article

References (39)

1. A. Jemal, R. Siegel, J. Xu, and E. Ward Cancer statistics, 2010 CA Cancer J Clin 60 2010 277 300
2. D.M. Parkin, F. Bray, J. Ferlay, and P. Pisani Global cancer statistics, 2002 CA Cancer J Clin 55 2005 74 108
3. M. Signorelli, V. Chiappa, L. Minig, R. Fruscio, P. Perego, and G. Caspani et al. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma Int J Gynecol Cancer 19 2009 1142 1146
4. D.K. Armstrong Relapsed ovarian cancer: challenges and management strategies for a chronic disease Oncologist 7 Suppl. 5 2002 20 28
5. A.P. Heintz, F. Odicino, P. Maisonneuve, M.A. Quinn, J.L. Benedet, and W.T. Creasman et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer Int J Gynaecol Obstet 95 Suppl. 1 2006 S161 S192
6. P. Harter, F. Hilpertm, S. Mahner, F. Heitz, J. Pfisterer, and A. du Bois Systemic therapy in recurrent ovarian cancer: current treatment options and new drugs Expert Rev Anticancer Ther 10 2010 81 88
7. N. Colombo, and M. Gore Treatment of recurrent ovarian cancer relapsing 6-12 months post platinum-based chemotherapy Crit Rev Oncol Hematol 64 2007 129 138
8. S.A. Cannistra, R.C. Bast Jr., J.S. Berek, M.A. Bookman, C.P. Crum, and P.D. DePriest et al. Progress in the management of gynecologic cancer: consensus summary statement J Clin Oncol 21 2003 129 132
9. T.J. Herzog, J.B. Vermorken, E. Pujade-Lauraine, J. Li, E. Bayever, and J. Gomez et al. Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone J Clin Oncol 27 2009 [abstract 5550]
10. E. Kobayashi, Y. Ueda, S. Matsuzaki, T. Yokoyama, T. Kimura, and K. Yoshino et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer Cancer Epidemiol Biomarkers Prev 21 2012 1902 1912
11. R. Longuespee, C. Boyon, A. Desmons, D. Vinatier, E. Leblanc, and I. Farre et al. Ovarian cancer molecular pathology Cancer Metastasis Rev 31 2012 713 732
12. A. Prat, M. Parera, B. Adamo, S. Peralta, M.A. Perez-Benavente, and A. Garcia et al. Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels Ann Oncol 20 2009 294 297
13. A. Prat, M. Parera, S. Peralta, M.A. Perez-Benavente, A. Garcia, and A. Gil-Moreno et al. Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer Ann Oncol 19 2008 327 331
14. E. Marco, M.H. David-Cordonnier, C. Bailly, C. Cuevas, and F. Gago Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA J Med Chem 49 2006 6925 6929
15. F. Gago Modelling and simulation: a computational perspective in anticancer drug discovery Curr Med Chem Anticancer Agents 4 2004 401 403
16. G. Germano, R. Frapolli, C. Belgiovine, A. Anselmo, S. Pesce, and M. Liguori et al. Role of macrophage targeting in the antitumor activity of trabectedin Cancer Cell 23 2013 249 262
17. J.A. Bueren-Calabuig, C. Giraudon, C.M. Galmarini, J.M. Egly, and F. Gago Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations Nucleic Acids Res 39 2011 8248 8257
18. S. Feuerhahn, C. Giraudon, M. Martinez-Diez, J.A. Bueren-Calabuig, C.M. Galmarini, and F. Gago et al. XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids Chem Biol 18 2011 988 999
19. J.A. Casado, P. Rio, E. Marco, V. Garcia-Hernandez, A. Domingo, and L. Perez et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin Mol Cancer Ther 7 2008 1309 1318
20. M. Romano, R. Frapolli, M. Zangarini, E. Bello, L. Porcu, and C.M. Galmarini et al. Comparison of in vitro and in vivo biological effects of trabectedin, lurbinectedin (PM01183) and Zalypsis(R) (PM00104) Int J Cancer 133 2013 2024 2033
21. A. Italiano, A. Laurand, A. Laroche, P. Casali, R. Sanfilippo, and A. Le Cesne et al. ERCC5/XPG, ERCC1, and BRCA1 gene status and clinical benefit of trabectedin in patients with soft tissue sarcoma Cancer 117 2011 3445 3456
22. P. Schoffski, M. Taron, J. Jimeno, F. Grosso, R. Sanfilipio, and P.G. Casali et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study Eur J Cancer 47 2011 1006 1012
23. B.J. Monk, T.J. Herzog, S.B. Kaye, C.N. Krasner, J.B. Vermorken, and F.M. Muggia et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer J Clin Oncol 28 2010 3107 3114
24. O.P. Kallioniemi, U. Wagner, J. Kononen, and G. Sauter Tissue microarray technology for high-throughput molecular profiling of cancer Hum Mol Genet 10 2001 657 662
25. C. Featherstone, and S.P. Jackson DNA repair: the Nijmegen breakage syndrome protein Curr Biol 8 1998 R622 R625
26. M. Digweed, A. Reis, and K. Sperling Nijmegen breakage syndrome: consequences of defective DNA double strand break repair Bioessays 21 1999 649 656
27. T.H. Stracker, and J.H. Petrini The MRE11 complex: starting from the ends Nat Rev Mol Cell Biol 12 2011 90 103
28. D. D'Amours, and S.P. Jackson The Mre11 complex: at the crossroads of dna repair and checkpoint signalling Nat Rev Mol Cell Biol 3 2002 317 327
29. R. Varon, C. Vissinga, M. Platzer, K.M. Cerosaletti, K.H. Chrzanowska, and K. Saar et al. Nibrin, a novel DNA double-strand break repair protein, is mutated in Nijmegen breakage syndrome Cell 93 1998 467 476
30. J. Plisiecka-Halasa, A. Dansonka-Mieszkowska, A. Rembiszewska, M. Bidzinski, J. Steffen, and J. Kupryjanczyk Nijmegen breakage syndrome gene (NBS1) alterations and its protein (nibrin) expression in human ovarian tumours Ann Hum Genet 66 2002 353 359
31. W. Cliby, S. Ritland, L. Hartmann, M. Dodson, K.C. Halling, and G. Keeney et al. Human epithelial ovarian cancer allelotype Cancer Res 53 1993 2393 2398
32. T.L. Yang-Feng, H. Han, K.C. Chen, S.B. Li, E.B. Claus, and M.L. Carcangiu et al. Allelic loss in ovarian cancer Int J Cancer 54 1993 546 551
33. H. Iwabuchi, M. Sakamoto, H. Sakunaga, Y.Y. Ma, M.L. Carcangiu, and D. Pinkel et al. Genetic analysis of benign, low-grade, and high-grade ovarian tumors Cancer Res 55 1995 6172 6180
34. R. Varon, E. Seemanova, K. Chrzanowska, O. Hnateyko, D. Piekutowska-Abramczuk, and M. Krajewska-Walasek et al. Clinical ascertainment of Nijmegen breakage syndrome (NBS) and prevalence of the major mutation, 657del5, in three Slav populations Eur J Hum Genet 8 2000 900 902
35. Group TINBSS Nijmegen breakage syndrome Arch Dis Child 82 2000 400 406
36. E. Seemanova An increased risk for malignant neoplasms in heterozygotes for a syndrome of microcephaly, normal intelligence, growth retardation, remarkable facies, immunodeficiency and chromosomal instability Mutat Res 238 1990 321 324
37. The Cancer Genome Atlas Research Network Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
38. J. Kang, A.D. D'Andrea, and D. Kozono A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy J Natl Cancer Inst 104 2012 670 681
39. E.M. Swisher, T. Taniguchi, and B.Y. Karlan Molecular scores to predict ovarian cancer outcomes: a worthy goal, but not ready for prime time J Natl Cancer Inst 104 2012 642 645